P
IBB icon

&Partners’s iShares Biotechnology ETF IBB Stock Holding History

&Partners’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.82M Buy
20,111
+487
+2% +$83.7K 0.02% 703
2026
Q1 		$3.31M Buy
19,624
+413
+2% +$70.6K 0.02% 688
2025
Q4 		$3.24M Buy
19,211
+3,462
+22% +$562K 0.02% 651
2025
Q3 		$2.27M Buy
15,749
+540
+4% +$73.7K 0.01% 701
2025
Q2 		$1.92M Buy
15,209
+195
+1% +$23.9K 0.01% 687
2025
Q1 		$1.96M Buy
15,014
+1,237
+9% +$168K 0.02% 545
2024
Q4 		$1.84M Buy
13,777
+4,635
+51% +$652K 0.02% 528
2024
Q3 		$1.33M Sell
9,142
-1,438
-14% -$208K 0.03% 461
2024
Q2 		$1.45M Buy
10,580
+4,197
+66% +$560K 0.06% 259
2024
Q1 		$876K Buy
6,383
+720
+13% +$98.3K 0.12% 169
2023
Q4 		$769K Sell
5,663
-153
-3% -$18.7K 0.19% 124
2023
Q3 		$711K Sell
5,816
-1,005
-15% -$128K 0.33% 60
2023
Q2 		$866K Buy
6,821
+30
+0.4% +$3.9K 0.39% 53
2023
Q1 		$877K Sell
6,791
-70
-1% -$9.16K 0.42% 49
2022
Q4 		$901K Sell
6,861
-117
-2% -$15.1K 0.45% 49
2022
Q3 		$816K Sell
6,978
-70
-1% -$8.69K 0.47% 50
2022
Q2 		$829K Hold
7,048
– – 0.48% 46
2022
Q1 		$918K Hold
7,048
– – 0.52% 44
2021
Q4 		$1.08M Hold
7,048
– – 0.65% 34
2021
Q3 		$1.14M Hold
7,048
– – 0.72% 33
2021
Q2 		$1.15M Hold
7,048
– – 0.75% 34
2021
Q1 		$1.06M Buy
7,048
+29
+0.4% +$4.61K 0.77% 34
2020
Q4 		$1.06M Buy
7,019
+176
+3% +$25.2K 0.89% 32
2020
Q3 		$927K Sell
6,843
-545
-7% -$73.9K 0.94% 32
2020
Q2 		$1.01M Sell
7,388
-268
-4% -$34.2K 1.22% 17
2020
Q1 		$825K Sell
7,656
-381
-5% -$43.9K 1.28% 16
2019
Q4 		$969K Hold
8,037
– – 1.15% 21
2019
Q3 		$800K Sell
8,037
-843
-9% -$88.2K 1.04% 21
2019
Q2 		$969K Sell
8,880
-320
-3% -$34K 1.34% 14
2019
Q1 		$1.03M Sell
9,200
-827
-8% -$90.7K 1.47% 12
2018
Q4 		$967K Buy
+10,027
New +$1.06M 1.62% 11

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

&Partners's IBB Position: Q2 2026 in Review

&Partners increased its iShares Biotechnology ETF (IBB) stake by 2.5% in Q2 2026, buying an estimated $83.7K and bringing the position to 20,111 shares worth $3.82M. The position accounts for 0.02% of the portfolio, ranked #703.

&Partners first reported a position in IBB in Q4 2018 and has held it in 31 quarters since. 955 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • &Partners held 20,111 shares of iShares Biotechnology ETF worth $3.82M as of Q2 2026.
  • &Partners bought 487 iShares Biotechnology ETF shares in Q2 2026, an estimated $83.7K.
  • iShares Biotechnology ETF made up 0.02% of &Partners's portfolio in Q2 2026, its #703 holding.
  • &Partners first reported a position in iShares Biotechnology ETF in Q4 2018 and has held it in 31 quarters since.
  • 955 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.